Sp1130

FOOD-MICROBIOME INTERACTIONS THAT DRIVE ABDOMINAL PAIN

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

Visceral pain is a leading cause of disability worldwide, affecting 20% of the population. Increased sensitivity to normal innocuous stimuli in the intestine is a hallmark of many organic and functional gastrointestinal disorders. A better understanding of the mechanisms associated with visceral hypersensitivity whether they include peripheral (eg microbiome-diet) or central inputs is necessary and critical in order to be able to treat patients. This workshop will present and discuss recent advances in our understanding of the factors that stimulate nociceptors of the intestine, and further central sensitization. Among the mechanisms that will be discussed are microbial factors, epithelial factors, immune mediators, and neuro-immune interactions, all studied in the setting of models, but also in patients' cohorts. This workshop is timely since cohorts of IBD patients are on-going aiming at phenotyping pain in such patients, and further identifying mechanisms associated with abdominal pain. Recent calls from national and international charities are supporting research on visceral pain, recognizing chronic pain as a priority research area. The implication of findings and potential treatments discussed should be of interest to a broad array of researchers from industrial, clinical and basic research background.

Presenter

Speaker Image for Giada De Palma
McMaster University

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for MICROBIOTA FROM PATIENTS WITH CROHN’S DISEASE INDUCES BEHAVIOURAL CHANGES IN MICROBIOTA-HUMANIZED MICE
MICROBIOTA FROM PATIENTS WITH CROHN’S DISEASE INDUCES BEHAVIOURAL CHANGES IN MICROBIOTA-HUMANIZED MICE
BACKGROUND AND AIMS: Peptostreptococcus stomatis (_P. stomatis_) is an enriched bacterium in colorectal cancer (CRC) patients as compared to healthy subjects in multiple cohorts. However, the potential role of _P. stomatis_ in colorectal tumorigenesis remains obscure…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA